This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
by Zacks Equity Research
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific
by Zacks Equity Research
GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
by Urmimala Biswas
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
GE HealthCare (GEHC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GE HealthCare Technologies (GEHC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 10.99% and 2.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zynex (ZYXI) delivered earnings and revenue surprises of -65% and 15.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
by Zacks Equity Research
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.
Stay Ahead of the Game With GE HealthCare (GEHC) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for GE HealthCare (GEHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
by Moumi Mondal
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
GE HealthCare (GEHC) Surges 10.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
GE HealthCare (GEHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GEHC Stock Gains Following Buyout Completion to Boost Its PDx Arm
by Zacks Equity Research
GE HealthCare aims to expand its existing footprint and offerings in Japan, as well as enhance patient access to next-generation radiopharmaceuticals via its latest acquisition.
GEHC Stock May Rise as Revolution Vibe CT Enhances Imaging Tech
by Zacks Equity Research
GE HealthCare introduces Revolution Vibe CT, a cutting-edge imaging system designed to enhance diagnostic precision, improve workflow efficiency, and expand accessibility.
GE HealthCare's Latest Product Launch to Boost Cardiology Care
by Zacks Equity Research
GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GEHC Stock Falls Despite New Launch to Boost Breast Cancer Diagnosis
by Zacks Equity Research
GE HealthCare aims to deliver optimal outcomes with its innovative, patient-friendly and efficient AI-driven technology via its latest product offering.
Here's Why You Should Hold GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GEHC Stock Gains Following Cardiology Solutions Portfolio Expansion
by Zacks Equity Research
GE HealthCare aims to enhance efficiency and precision care for multiple types of cardiac procedures through the introduction of improved interventional solutions.
GEHC Stock Gains in Pre-Market Following Tie-Up Expansion With NVIDIA
by Zacks Equity Research
GE HealthCare aims to unlock automated solutions that enhance efficiency, easing the burden of increased volumes and staff shortages on healthcare professionals.
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic
by Zacks Equity Research
NVIDIA, Resmed, GE HealthCare and Medtronic are part of the Zacks top Analyst Blog.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
by Urmimala Biswas
RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.
GEHC Stock May Gain as Genesis Portfolio Expands Cloud Offerings
by Zacks Equity Research
GE HealthCare unveils Genesis, a cloud-based imaging portfolio designed to enhance healthcare efficiency, streamline data access, and drive digital transformation.
Earnings Growth & Price Strength Make GE HealthCare Technologies (GEHC) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.